Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant, recognizing research from the Melanoma Institute Australia, the University of Turin in Italy and Atrium Health Wake Forest Baptist Medical Center.
The grant program, now in its seventh round of awardees, supports investigator-initiated studies with the aim to increase high-quality molecular profiling in oncology and to help democratize precision medicine.
Based on the last call for proposals in Spring 2023, the following researchers and projects have been selected as the most recent grant recipients:
- Richard Scolyer, Melanoma Institute Australia, The University of Sydney, Royal Prince Alfred Hospital, Australia – “Getting melanoma diagnosis right: migration of clinical validation of the MIA genomic ancillary test on the Genexus platform for regular clinical testing.”
- Researchers will use the Ion Torrent Genexus system to migrate the Melanoma Institute Australia’s genomic classifier into routine clinical testing.
- Silvia Novello and Marco Volante, University of Turin, Italy – “Integrated molecular analysis to depict signatures associated with TKI treatment response in advanced NSCLC and to identify novel predictive biomarkers.”
- Researchers will work to fill an unmet need in precision oncology and will identify novel clinically relevant biomarkers of response to TKI in specific oncogene-addicted scenarios and increase the amount of available predictive tools of therapeutic responsiveness at baseline.
- Wencheng Li, Atrium Health Wake Forest Baptist Medical Center, United States of America – “Biomarker Assessment by Next Generation Sequencing Using the Supernatants from Fine Needle Aspiration of NSCLC.”
- Researchers will work to identify solutions for frequently encountered problems (inadequate specimen, indeterminate diagnosis, less-than-optimal turnaround time and false negative result) in NSCLC diagnosis and treatment.
Applications for the Spring 2024 round of the Oncomine Clinical Research Grant will open March 1, 2024, and close April 30, 2024. Successful proposals should address the molecular landscape of tumors, with a focus on how molecular testing can enhance treatment precision and unlock novel strategies for improving patient outcomes. Proposals should include an outline of planned activities to be performed within a maximum of 12 months, as well as an outline of the proposed use of the requested funds.
For more information, please visit www.oncomine.com/grants.
